Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mapping the clinical outcomes and genetic evolution of Ebola virus in Sierra Leone
Tao Li, … , Hui Wang, Wu-Chun Cao
Tao Li, … , Hui Wang, Wu-Chun Cao
Published August 3, 2017
Citation Information: JCI Insight. 2017;2(15):e88333. https://doi.org/10.1172/jci.insight.88333.
View: Text | PDF
Research Article Genetics

Mapping the clinical outcomes and genetic evolution of Ebola virus in Sierra Leone

  • Text
  • PDF
Abstract

Sierra Leone was the most severely affected country in Western Africa during the 2013–2016 outbreak of Ebola virus disease (EVD). Previous genome surveillance studies have revealed the origin, diversity, and evolutionary dynamics of the Ebola virus (EBOV); however, the information regarding EBOV sequences is insufficient, especially the clinical outcomes, given that the correlation between the clinical outcomes and the genetic evolution of EBOV is still not clear. Here, we collected and curated a comprehensive data set that includes 514 EBOV genome sequences from patients with confirmed EVD (including 60 sequences not previously studied), >87.5% of which have residence information and definitive clinical outcomes. Phylogenetic reconstruction revealed 11 lineages of EBOV in Sierra Leone. The median-joining haplotype network showed that haplotypes that are associated with lethal outcomes tend to contribute more to the spread of the EBOV in Sierra Leone than those with live outcomes. Analyses of the spatial-temporal distribution unraveled the lineage-distinctive distribution patterns. Different viral lineages have different case fatality rates (CFRs) during the same stage of the outbreak, implying that several lineages featuring SNPs may correlate with increased/decreased CFRs. This study provides invaluable data sets of EBOV infection and highlights the potential SNPs for further in-depth investigation.

Authors

Tao Li, Hong-Wu Yao, Di Liu, Hong-Guang Ren, Yi Hu, David Kargbo, Yue Teng, Yong-Qiang Deng, Hui-Jun Lu, Xiong Liu, Kun Liu, Li-Qun Fang, Nian-Zhi Ning, Gary Wong, Foday Dafae, Abdul Kamara, AiPing Wu, Tai-Jiao Jiang, Zhan Li, Jie Huang, Yu Sun, Jun Qian, Brima Kargbo, Jia-Fu Jiang, Hui Wang, Wu-Chun Cao

×

Figure 1

Phylogenetic analysis of EBOV, with clinical outcomes of patients in Sierra Leone.

Options: View larger image (or click on image) Download as PowerPoint
Phylogenetic analysis of EBOV, with clinical outcomes of patients in Sie...
(A) A Bayesian phylogenetic tree of 514 EBOV sequences from Sierra Leone and 3 early EBOV sequences from Guinea. The patient clinical outcome information is indicated by color. Posterior support for major nodes is shown. SL3.1* means the other EBOV cases in SL3.1, except SL3.1.1, SL3.1.2, SL3.1.3, and SL3.1.4. SL3.2* means the other EBOV cases in SL3.2, except SL3.2.1, SL3.2.2, SL3.2.3, SL3.2.4, and SL3.2.5. Posterior support for major nodes is shown. (B) Median-joining haplotype network for the EBOV sequences. The patient clinical outcomes are shown in different colors. (C) The number and degree of the pure-live and pure-lethal intermediate haplotypes in each lineage of EBOV.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts